Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 76-100 of 125

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
177Lu Girentuximab in Combination with Cabozantinib and Nivolumab for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Retifanlimab and Ruxolitinib for the Treatment of Advanced or Metastatic Renal Cell Cancer or Non-small Cell Lung Cancer Progressing on Prior Checkpoint Inhibition, PRISM Trial
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: 2 locations
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Evaluating the Impact of Cabozantinib with Nivolumab on the Bone Immune Microenvironment in Treating Metastatic Clear Cell Renal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapy (Nivolumab and Ipilimumab) with and without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Status: Active
Location: 2 locations
Nivolumab and Ipilimumab with and without Camu Camu for the Treatment of Patients with Metastatic Renal Cell Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Genetically Engineered Cells (TGFβR-2 KO CD70 CAR NK Cell Therapy) with Lymphodepleting Chemotherapy for the Treatment of Unresectable or Metastatic Refractory Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients with Solid Tumor Cancers Being Treated with Standard of Care Checkpoint Inhibitors
Status: Active
Location: 5 locations
Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas